Using a closure analysis method to reduce CGT contamination risks
Many cell therapy manufacturing processes use open unit manipulations. As a result, they are at risk of potential contam...
High Level Analytics
Viewing related articles
Feedback to MHRA / British Pharmacopoeia: Guidance on the application of vector copy number for the cell and gene therapy community​
A BioPhorum member only summary document detailing consolidated feedback and suggested recommendations from the High-Level Analytics team on MHRA / British Pharmacopoeia: Guidance on the application of vector copy number for the cell and gene therapy community​.
Feedback to MHRA / British Pharmacopoeia: Guidance on the application of flow cytometry for the cell and gene therapy community​
Summary of member feedback and recommendations on British Pharmacopoeia: Guidance on the application of flow cytometry for the cell and gene therapy community. A member only document.
Challenges for potency assay development for in vivo and ex vivo gene therapies and the matrix approach
This paper highlights some of the challenges to develop potency assays for gene therapies and promotes a potential solution. It seeks to establish Industry alignment on the benefits of a matrix approach and provides high level guidance on how to adopt this strategy towards potency assay development and validation with examples for in vivo and ex vivo GT processes.